Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma

Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer

(2022) Bingnan Zhang et al.   BRITISH JOURNAL OF CANCER

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors

(2021) Ukhyun Jo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243

(2021) Yasuhisa Murai et al.   CANCER RESEARCH

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

(2021) Lauren Averett Byers et al.   CLINICAL CANCER RESEARCH

RBM10: Structure, functions, and associated diseases

(2021) Akira Inoue   GENE

A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers

(2021) Bingnan Zhang et al.   BRITISH JOURNAL OF CANCER

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer

(2021) Claudia Winkler et al.   JCI Insight

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer

(2021) Victoria Tserpeli et al.   Cancers

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features

(2020) Changyu Zhu et al.   JOURNAL OF HEPATOLOGY

Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans

(2020) Haichuan Wang et al.   HEPATOLOGY

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing

(2019) Riccardo Mezzadra et al.   PLoS One

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade

(2019) Ying Zhu et al.   GUT

Macrophages and hepatocellular carcinoma

(2019) Zhiqiang Tian et al.   Cell and Bioscience

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

(2019) Liang-qing Dong et al.   JOURNAL OF HEPATOLOGY

Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

(2018) David Linehan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

SLFN11 Blocks Stressed Replication Forks Independently of ATR

(2018) Junko Murai et al.   MOLECULAR CELL

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection

(2018) Chenhao Zhou et al.   Cancer Medicine

Notch Signaling in the Tumor Microenvironment

(2018) Olivier Meurette et al.   CANCER CELL

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Integrin CD11b activation drives anti-tumor innate immunity

(2018) Michael C. Schmid et al.   Nature Communications

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

(2017) Jun Chen et al.   NATURE

An RRM–ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion

(2017) Katherine M. Collins et al.   NUCLEIC ACIDS RESEARCH

A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer

(2017) Wenbo Yao et al.   EBioMedicine

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

(2015) Xiaoguang Li et al.   GUT

F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner

(2015) Kanae Yumimoto et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Advances in targeted therapies for hepatocellular carcinoma in the genomic era

(2015) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

(2013) Shahneen K. Sandhu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

(2013) Martin Franz Sprinzl et al.   HEPATOLOGY

RBM5, 6, and 10 Differentially Regulate NUMB Alternative Splicing to Control Cancer Cell Proliferation

(2013) Elias G. Bechara et al.   MOLECULAR CELL

Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11

(2012) Manqing Li et al.   NATURE

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE